SCHEMBL916307

SCHEMBL916307

CCOC(=O)Nc1ccc2ccn([Si](C(C)C)(C(C)C)C(C)C)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.45
MAPK1 P28482 2/20 0.45
HSD17B10 Q99714 2/20 0.45
LMNA P02545 1/20 0.45
NPC1 O15118 5/20 0.43
RAB9A P51151 4/20 0.43
HTT P42858 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
ALDH1A1 P00352 5/20 0.43
HPGD P15428 4/20 0.43
POLB P06746 2/20 0.43
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
ELANE P08246 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12903454 0.80 ALDH1A1 (0.51) MAPTMAPK1HSD17B10LMNANPC1
SCHEMBL29522898 0.74 ALDH1A1 (0.50) MAPTMAPK1HSD17B10LMNANPC1
SCHEMBL28490404 0.74 ALDH1A1 (0.50) MAPTMAPK1HSD17B10LMNANPC1
SCHEMBL11647953 0.70 ALDH1A1 (0.47) MAPTMAPK1HSD17B10LMNANPC1
SCHEMBL7565149 0.70 MAPK1 (0.81) MAPTMAPK1HSD17B10LMNANPC1
SCHEMBL6270218 0.69 RAB9A (0.63) MAPTMAPK1HSD17B10LMNANPC1
SCHEMBL7565510 0.69 RAB9A (0.71) MAPTMAPK1HSD17B10LMNANPC1
SCHEMBL11767621 0.69 KDM4E (0.70) MAPTMAPK1HSD17B10LMNANPC1
SCHEMBL3822402 0.68 POLB (0.56) MAPTMAPK1HSD17B10LMNANPC1
SCHEMBL8695229 0.68 ALDH1A1 (0.72) MAPTMAPK1HSD17B10LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009428-A1 NOVEL ANDROGENS N.V. ORGANON (NL) 2011-01-13 US disclosed
US-20110009428-A1 NOVEL ANDROGENS N.V. ORGANON (NL) 2011-01-13 US disclosed
US-7812036-B2 Androgens N.V. ORGANON (NL) 2010-10-12 US disclosed
EP-1742912-B1 NOVEL ANDROGENS ORGANON NV (NL) 2010-08-25 EP disclosed
US-20070225352-A1 Novel Androgens PHARMACOPELA DRUG DISCOVERY, INC. (US) 2007-09-27 US disclosed
US-20070225352-A1 Novel Androgens PHARMACOPELA DRUG DISCOVERY, INC. (US) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225352-A1 Novel Androgens NR5A1, AR, SHBG MAPT 1573/4885MAPK1 2237/4885HSD17B10 38/4885
US-20110009428-A1 NOVEL ANDROGENS NR5A1, AR, NR3C2 MAPT 4558/4885MAPK1 3221/4885HSD17B10 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.